Fig. 5
EPO delivery in vivo by EF1α-mEPO transposon-modified T lymphocytes. a Schematic representation of experiment evaluating ability of adoptively transferred transposon-modified T lymphocytes to produce EPO following adoptive cell transfer. b Graph of plasma EPO concentration in the days following ACT of 2 × 107 million EF1α-mEPO transposon-modified T lymphocytes. Statistical analysis was performed by comparing two pre-treatment levels using one-way ANOVA with multiple comparisons (N = 5 ± SEM). Red arrow indicates administration of cellular vaccine at day 41. c Graph comparing hematocrit 6 weeks after ACT (mice from b) to that of untreated control mice. The mean hematocrit of treated mice was 62.8 ± 3.2 (N = 5 ± SEM) and untreated mice was 47 ± 1.4 (N = 6 ± SEM), *p < 0.05 using Student’s T-test
